Abstract: By inserting a DNA or RNA sequence comprising a subsequence showing a homology of at least 60%, preferably at least 80%, and most preferably at least 90% of the DNA sequence of SEQ. ID. NO. 1 into a cell, that cell will obtain a broad specificity for changing nucleoside analog prodrugs to active drugs by phosphorylation. Likewise this changement will occur at a high catalytic rate. Preferably the DNA sequence is inserted into the cell by transformation with a suitable virus or another suitable vector. Such viruses and vectors also constitute a part of the present invention.
Abstract: Organisms are provided which express enzymes such as glycerol dehydratase, diol dehydratase, acyl-CoA transferase, acyl-CoA synthetase &bgr;-ketothiolase, acetoacetyl-CoA reductase, PHA synthase, glycerol-3-phosphate dehydrogenase and glycerol-3-phosphatase, which are useful for the production of PHAs. In some cases one or more of these genes are native to the host organism and the remainder are provided from transgenes. These organisms produce poly (3-hydroxyalkanoate) homopolymers or co-polymers incorporating 3-hydroxypropionate or 3-hydroxyvalerate monomers wherein the 3-hydroxypropionate and 3-hydroxyvalreate units are derived from the enzyme catalysed conversion of diols. Suitable diols that can be used include 1,2-propanediol, 1,3 propanediol and glycerol. Biochemical pathways for obtaining the glycerol from normal cellular metabolites are also described.
Abstract: Compositions and methods are provided for treating NF-&kgr;B-related conditions. In particular, the invention provides a stimulus-inducible IKK signalsome, and components and variants thereof. An IKK signalsome or component thereof may be used, for example, to identify antibodies and other modulating agents that inhibit or activate signal transduction via the NF-&kgr;B cascade. IKK signalsome, components thereof and/or modulating agents may also be used for the treatment of diseases associated with NF-&kgr;B activation.
Type:
Grant
Filed:
April 27, 2001
Date of Patent:
June 10, 2003
Assignee:
Signal Pharmaceuticals, Inc.
Inventors:
Frank Mercurio, Hengyi Zhu, Miguel Barbosa, Jian Wu Li, Brion W. Murray
Abstract: Provided is the active site of human gamma glutamyl hydrolase. The active site resides in amino acid residues 110, 171, 220 and 222 of SEQ ID NO:1. Thus provided is an inactive gamma glutamyl hydrolase protein, as well as a fragment thereof. A method of inactivating a gamma glutamyl hydrolase protein is also provided, as is a molecule capable of binding to one or more of amino acid residues 110, 171, 220 or 222 of SEQ ID NO:1 which can be used in such a method. A method for identifying a molecule that inactivates gamma glutamyl hydrolase is provided, as is a nucleic acid molecule encoding the inactive gamma glutamyl hydrolase.
Type:
Grant
Filed:
June 4, 1999
Date of Patent:
June 3, 2003
Assignee:
Health Research Incorporated
Inventors:
John H. Galivan, Thomas J. Ryan, Ivan E. Auger
Abstract: The invention provides isolated nucleic acid molecules, designated DHY nucleic acid molecules, which encode novel DHY-related dehydratase molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing DHY nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DHY gene has been introduced or disrupted. The invention still further provides isolated DHY proteins, fusion proteins, antigenic peptides and anti-DHY antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
Abstract: Polypeptides having the amino acid sequence represented by SEQ ID NO:1 or derived therefrom by at least one of deletion, addition, insertion or substitution of one or more amino acids in the above sequence and showing a cellobiohydrolase activity.
Abstract: This invention relates to a novel metalloprotease having a proteolytic activity, its partial peptide or a salt either of them, a DNA coding for the protein, a recombinant vector comprising the DNA, a transformant carrying the recombinant vector, a process for producing the protein, a pharmaceutical composition comprising the DNA, an antibody against the protein, a method for screening for a compound which activates or inhibits a proteolytic activity of the protein, a kit for screening for the compound, and a compound which activates or inhibits a proteolytic activity of the protein which is identified by the screening method or the kit. The DNA coding for the protein of the present invention can be used as a therapeutic and prophylactic composition for a variety of diseases including diabetic nephropathy, glomerulonephritis, pulmonary fibrosis, hepatolienal fibrosis, hepatocirrhosis, osteopetrosis and herniated disk.
Abstract: A novel cellulase composition is provided which is predicable by an Actinomycete. The cellulase has an approximate calculated molecular weight of 36 kD and has a pH optimum at 40° C. of 8 and at 60° C. of 7. Also provided is a DNA encoding said cellulase, a method for producing the cellulase and applications thereof.
Type:
Grant
Filed:
February 27, 2001
Date of Patent:
May 20, 2003
Assignee:
Genencor International, Inc.
Inventors:
Brian E. Jones, Wilhelmus A. H. Van Der Kleij, Piet Van Solingen, Walter Weyler
Abstract: The present invention relates to means for the detection and characterization of nucleic acid sequences, as well as variations in nucleic acid sequences. The present invention also relates to improved cleavage means for the detection and characterization of nucleic acid sequences. Structure-specific nucleases derived from a variety of thermostable organisms are provided. These structure-specific nucleases are used to cleave target-dependent cleavage structures, thereby indicating the presence of specific nucleic acid sequences or specific variations thereof.
Type:
Grant
Filed:
October 8, 1999
Date of Patent:
May 13, 2003
Assignee:
Third Wave Technologies, Ins.
Inventors:
Michael W. Kaiser, Victor I. Lyamichev, Natasha Lyamicheva
Abstract: A novel cellulase composition is provided which is produced by an Actinomycete. The cellulase has an approximate calculated molecular weight of 36 kD and has a pH optimum at 40° C. of 8 and at 60° C. of 7. Also provided is a DNA encoding said cellulase, a method for producing the cellulase and applications thereof.
Type:
Grant
Filed:
December 18, 2000
Date of Patent:
May 13, 2003
Assignee:
Genencor International, Inc.
Inventors:
Brian E. Jones, Wilhelmus A. H. Van Der Kleij, Piet Van Solingen, Walter Weyler, Frits Goedegebuur
Abstract: Two cellobiohydrolase polypeptides (CBHA and CBHB) derived from Aspergillus are described and can be used to degrade cellulose. Variants of these peptides are described as well as DNA encoding the peptides, vectors and host cells. The peptides can be used to produce or process food, animal feed, wood pulp, paper and textiles.
Type:
Grant
Filed:
April 4, 2000
Date of Patent:
May 6, 2003
Assignee:
DSM N.V.
Inventors:
Marcus Matheus Catharina Gielkens, Jacob Visser, Leendert Hendrik De Graaff
Abstract: The present invention relates to means for the detection and characterization of nucleic acid sequences, as well as variations in nucleic acid sequences. The present invention also relates to improved cleavage means for the detection and characterization of nucleic acid sequences. Structure-specific nucleases derived from a variety of thermostable organisms are provided. These structure-specific nucleases are used to cleave target-dependent cleavage structures, thereby indicating the presence of specific nucleic acid sequences or specific variations thereof.
Type:
Grant
Filed:
October 6, 2000
Date of Patent:
April 29, 2003
Assignee:
Third Wave Technologies, Inc.
Inventors:
Michael W. Kaiser, Victor I. Lyamichev, Natasha Lyamicheva
Abstract: A method for controlling and modifying biopolymer synthesis by manipulation of the genetics and enzymology of synthesis of polyhydroxybutyrate (PHB) and polyhydroxyalkanoate (PHA) polyesters at the molecular level in procaryotic and eukaryotic cells, especially plants. Examples demonstrate the isolation, characterization, and expression of the genes involved in the production of PHB and PHA polymers. Genes encoding the enzymes in the PHB and PHA synthetic pathway (beta-ketothiolase, acetoacetyl-CoA reductase and PHB polymerase or PHA polymerase) from Zoogloea ramigera strain I-16-M, Alcaligenes eutrophus, Nocardia salmonicolur, and Psuedomonas olevarans were identified or isolated and expressed in a non-PHB producing organism, E. coli. Specific modifications to the polymers include variation in the chain length of the polymers and incorporation of different monomers into the polymers to produce co-polymers with different physical properties.
Abstract: The present invention relates to the identification of metalloproteases in gram positive microorganisms and provides the nucleic acid and amino acid sequences for a metalloprotease. Host cells having a mutation or deletion of part or all of the gene encoding the metalloprotease wherein the mutation or deletion results in inactivation of the proteolytic activity of the metalloprotease are also part of the invention.
Abstract: The present invention relates to a site-specific endonuclease which recognizes a specific nucleotide sequence, to a gene coding for the endonuclease, to a recombinant vector containing the gene, to a transformant containing the vector, and to a process for producing the endonuclease.
Type:
Grant
Filed:
August 20, 2001
Date of Patent:
March 4, 2003
Assignee:
Institute of Physical and Chemical Research
Abstract: Antigens capable of eliciting antibodies which can enhance the rate of chemical reactions at peptide bonds are disclosed. In particular, the rate of cleavage or formation of metastable peptide bonds, such as ASN-X, ASP-X, GLN-X, GLU-X, LYS-X, and HIS-Y-X, where X and Y are any amino acid, is enhanced by antibodies elicited by said antigen.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
February 18, 2003
Assignee:
IGEN International, Inc.
Inventors:
Michael J. Powell, Anthony R. Rees, Paul M. Booth, Wonpyo Hong, Richard C. Titmas, Richard J. Massey
Abstract: The present invention is directed generally to catalytic antibodies and, more particularly, to a novel method of producing same. The method of the present invention is predicated in part on the exploitation of the products of catalysis to induce B cell mitogenesis. In a preferred embodiment, a growth factor having an ability to induce B cell mitogenesis is linked to a target antigen to which catalytic antibodies are sought. B cell mitogenesis is then dependent on the catalytic cleavage of the antigen portion of the growth factor by catalytic antibodies on the surface of B cells. The method of the present invention is useful for generating catalytic antibodies for both therapeutic and diagnostic purposes.
Type:
Grant
Filed:
November 9, 2000
Date of Patent:
February 18, 2003
Assignee:
Frank Koentgen Pty Ltd.
Inventors:
Frank Koentgen, Gabriele Maria Suess, David Mathew Tarlinton, Herbert Rudolf Treutlein
Abstract: An isolated polypeptide (JNK) characterized by having a molecular weight of 46kD as determined by reducing SDS-PAGE, having serine and threonine kinase activity, phosphorylating the c-Jun N-terminal activation domain and polynucleotide sequences and method of detection of JNK are provided herein. JNK phosphorylates c-Jun N-terminal activation domain which affects gene expression from AP-1 sites.
Type:
Grant
Filed:
March 25, 1994
Date of Patent:
February 4, 2003
Assignee:
The Regents of the University of California
Inventors:
Michael Karin, Masahiko Hibi, Anning Lin, Roger Davis, Benoit Derijard
Abstract: The present invention discloses a unique vertebrate protein, tankyrase that binds to telomeric repeat binding factor 1 (TRF1). Nucleic acids encoding tankyrases are also disclosed. Methods of screening drugs using tankyrase are also included.